Exagen Inc. (NASDAQ: XGN) reported Q4 EPS of ($0.83), $0.06 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $12.8 million versus the consensus estimate of $8.66 million.

GUIDANCE:

Exagen Inc. sees Q1 2023 revenue of $9.2-9.7 million, versus the consensus of $9.3 million.

For earnings history and earnings-related data on Exagen Inc. (XGN) click here.